Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
SG | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Oct 28, 22 | -0.16
Decreased by
-128.57%
|
-0.19
Increased by
+15.79%
|
Aug 12, 22 | -0.19
Decreased by
-46.15%
|
-0.20
Increased by
+5.00%
|
Mar 25, 22 | -0.16
Decreased by
-6.67%
|
-0.14
Decreased by
-14.29%
|
Oct 26, 21 | -0.12
Decreased by
-20.00%
|
-0.13
Increased by
+7.69%
|
Aug 6, 21 | -0.07
Increased by
+30.00%
|
-0.11
Increased by
+36.36%
|
May 11, 21 | -0.13
Decreased by
-30.00%
|
-0.11
Decreased by
-18.18%
|
Apr 22, 21 | -0.15
Increased by
+83.33%
|
-0.10
Decreased by
-50.00%
|
Nov 9, 20 | -0.10
Increased by
+33.33%
|
-0.09
Decreased by
-11.11%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-10.93 M
Decreased by
-235.15%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-13.03 M
Decreased by
-229.23%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-8.55 M
Decreased by
-64.98%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-5.43 M
Increased by
+31.55%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 20 | 0.00
Decreased by
N/A%
|
-3.26 M
Increased by
+70.94%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 20 | 0.00
Decreased by
N/A%
|
-3.96 M
Increased by
+63.33%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 19 | 0.00
Decreased by
N/A%
|
-5.19 M
Increased by
+34.53%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 19 | 0.00
Decreased by
N/A%
|
-7.93 M
Increased by
+13.77%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.